The arrival of the drug in the country is creating significant interest within the healthcare community. This innovative dual agonist – acting on both GLP-1 and GIP receptors – presents a remarkably powerful tool https://australianpeptidestore.co/bpc-157-10mg-research-peptide-australian-peptide-store/